Tim Doyle

And as someone who's kind of treated a lot of weight loss patients, side effect profile really matters.

And so...

I think Manjaro will be the king of the category for the foreseeable.

Um, and then the other thing that I think is interesting is, and then, but the bull case on Lily is like, they are not just an insulin and weight loss company anymore.

Like they have done incredible.

Have you seen the, like the stuff they do with the gene editing PCSK9s recently, the paper that came out last week?

Uh, they're a phenomenal company, like a phenomenal, like truly, like, I just think like ultimately I went to their 150th birthday last week and, um, it's,

It's one of those companies where you just leave talking to them, particularly to their scientists, being in awe of what's possible.

I find it absolutely fucking crazy that people are pessimistic about an AI-driven future, given how much better life can be.

Yeah, yeah, yeah, it'll be hard.

There'll be parts that are crazy and scary and risky, but that has been true forever.

And you talk to Eli Lilly and you go like, oh my God, the number of...

I don't think, it wasn't Eli Lilly who had this drug come out last week, but there was a drug that came out last week, which was like double the length, the expected length of life with pancreatic cancer.

It's obviously just been a killer for a while.

And the rate at which these drug discoveries are happening is just so incredible that I think like, and Lilly are the best of all these companies.

And so I think there's a lot to be excited about for them outside of weight, but I think their dominance of weight

It's certainly going to be challenged.

But the last couple of years, they've been just incredible.

Yeah, good podcast guest, right?

Yeah.